Aug. 4 at 3:16 PM
$HRTX Very promising, based on the latest data we've received. Zynrelef&Aponvie seem to be growing very well. Look at Exparel, which many see as somewhat inferior to Zynrelef in its overall attributes (benefits from being a well-established product). Exparel has been on the market since 2011 and reached
$575M in revenue in 2025. It takes time. It's not Ozempic.
Now it's ZYNRELEF time to grow strongly YoY, and APONVIE looks like it's going to double its 2025 revenue +
Not bad at all... maybe not
$100 potential based on its current medicines, but if all goes well,
$15 over time is realistic. What's wrong with that?
From personal experience, when I first bought Xeris shares, it was the day Recorlev for Cushing's was approved. At first, Recorlev potential was estimated at
$250M. Now it's projected at
$1B, + even stronger medicine in phase 3.
So today Heron may have
$15 potential, but in a few years, while building on its foundation and adding more, it could become a
$50 opportunity.
